Clinical Trials
Open
Phase
Accrual
24%
SWOG Clinical Trial Number
S2104
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10-14-2021
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S2011
Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL
Status Notes
The study referenced above is closed to participant accrual effective November 15th, 2023, at 3:00 p.m. Eastern Time.
Research Committee(s)
Genitourinary Cancer
Activated
10-06-2021
Closed
11-15-2023
ClinicalTrials.gov Registry Number
04871529
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S1934
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Status Notes
S1934 is permanently closed effective 3/1/2023.
Research Committee(s)
Lung Cancer
Activated
09-09-2021
Closed
03-01-2023
ClinicalTrials.gov Registry Number
04989283
Open
Phase
Accrual
94%
SWOG Clinical Trial Number
S2013
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Status Notes
S2013 will open to accrual on August 16, 2021, effective 12:00 pm PST.
Research Committee(s)
Symptom Control and Quality of Life
Activated
08-16-2021
Open
Phase
Accrual
66%
SWOG Clinical Trial Number
S1912CD
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Status Notes
All protocol documents will be accessible from the S1912CD protocol abstract page on www.ctsu.org (login required).
Research Committee(s)
Cancer Care Delivery
Activated
07-26-2021
ClinicalTrials.gov Registry Number
NCT 04960787
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2005
A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
Status Notes
Re-Activation – Effective (9/20/2021)
Research Committee(s)
Myeloma
Activated
06-24-2021
ClinicalTrials.gov Registry Number
04840602
Open
Phase
Accrual
96%
SWOG Clinical Trial Number
S1900E
A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Status Notes
S1900E will open to accrual April 2, 2021, effective 12:00 pm PST.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
04-02-2021
Open
Phase
Accrual
22%
SWOG Clinical Trial Number
S1918
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Status Notes
Activation - Effective 3/19/21, 12:00 pm Pacific Time
Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.
Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.
Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.
Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.
Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Research Committee(s)
Lymphoma
Activated
03-19-2021
ClinicalTrials.gov Registry Number
04799275
Open
Phase
Accrual
14%
SWOG Clinical Trial Number
S1937
A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.
Status Notes
Arm 2 will be Permanently Closed to Accrual and Arms 1 & 3 will be Reopened to Accrual as of 02/15/2024, 12 PM PST.
Research Committee(s)
Genitourinary Cancer
Activated
02-16-2021
ClinicalTrials.gov Registry Number
NCT04579224
Open
Phase
Accrual
55%
SWOG Clinical Trial Number
S2007
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Status Notes
Activation - Effective 12/15/20, 12:00 PM Pacific Time
All protocol documents will be accessible from the S2007 protocol abstract page on www.ctsu.org after activation on 12/15/20 (login required).
All protocol documents will be accessible from the S2007 protocol abstract page on www.ctsu.org after activation on 12/15/20 (login required).
Research Committee(s)
Breast Cancer
Activated
12-15-2020
ClinicalTrials.gov Registry Number
04647916
Open
Phase
Accrual
38%
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Status Notes
Active effective 12/14/20
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12-14-2020
ClinicalTrials.gov Registry Number
04269902
Open
Phase
Accrual
53%
SWOG Clinical Trial Number
S2001
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects
Status Notes
Activation, Effective 12/04/2020, 3:00 pm eastern
Research Committee(s)
Gastrointestinal Cancer
Activated
12-04-2020
ClinicalTrials.gov Registry Number
NCT04548752
Open
Phase
Accrual
27%
SWOG Clinical Trial Number
S1931
Phase III trial of Nivolumab and Ipilimumab with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Status Notes
Active effective 11/16/2020
Research Committee(s)
Genitourinary Cancer
Activated
11-16-2020
Open
Phase
Accrual
91%
SWOG Clinical Trial Number
S2000
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Status Notes
Activation, Effective 9/23/2020, 2:00 pm eastern
Research Committee(s)
Melanoma
Activated
09-23-2020
ClinicalTrials.gov Registry Number
NCT04511013
Open
Phase
Accrual
93%
SWOG Clinical Trial Number
S1904
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)
Research Committee(s)
Prevention & Epidemiology
Breast Cancer
Activated
09-01-2020
ClinicalTrials.gov Registry Number
NCT 04496739
Open
Phase
Accrual
22%
SWOG Clinical Trial Number
S1905
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Status Notes
Re-opened to accrual effective: 10/02/2023.
Research Committee(s)
Leukemia
Activated
08-17-2020
ClinicalTrials.gov Registry Number
NCT#04315324
Open
Phase
Accrual
74%
SWOG Clinical Trial Number
S1933
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
Status Notes
This study is open to accrual effective June 15, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
NCT04310020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1929
Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)
Status Notes
S1929 will open to accrual June 15, 2020, effective 12:00 pm PST.
Effective August 15, 2022, at 3:45 a.m. Pacific Time, S1929 Step 1 Screening Registration will be permanently closed to accrual, as it has met the protocol specified accrual goal.
Effective August 15, 2022, at 3:45 a.m. Pacific Time, S1929 Step 1 Screening Registration will be permanently closed to accrual, as it has met the protocol specified accrual goal.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
Closed
12-15-2022
ClinicalTrials.gov Registry Number
04334941
Open
Phase
Accrual
96%
SWOG Clinical Trial Number
S1823
A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors
Status Notes
Effective April 15, 2022, the study will be partial permanently closed to the high risk of relapse group (except for testicular nonseminoma Stage IS).
Research Committee(s)
Prevention & Epidemiology
Genitourinary Cancer
Activated
06-01-2020
Open
Phase
Accrual
71%
SWOG Clinical Trial Number
S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
Status Notes
This study is open to accrual effective March 25, 2020.
Research Committee(s)
Lung Cancer
Activated
03-25-2020
ClinicalTrials.gov Registry Number
04214262